Investor Presentaiton

DNA Financial objectives and dividend policy DNA financial guidance¹ for 2019 Mid-term financial targets DNA's net sales are expected to remain at the same level as in 2018, and EBITDA is expected to increase substantially from 2018. DNA's financial position and liquidity are expected to remain at a healthy level. The adoption of IFRS 16 from the beginning of 2019, is estimated to have a 17 million euros positive impact in EBITDA in 2019. The impact of IFRS 16 on operating result (EBIT) is insignificant. Net sales growth - faster than average market growth EBITDA margin of at least 34% (previous target was 32%), including IFRS16 impact Operative capital expenditure² less than 15% of sales Leverage policy Board's proposal for dividend for 2019 AGM Net debt/EBITDA less than 2.0 Can be temporarily exceeded in case of potential attractive bolt-on in-market M&A opportunities Board's dividend proposal for the 2018 financial year: EUR 0.70 per share and an extra dividend of EUR 0.40 per share In total EUR 1.10 per share, 6.4% payout ratio (as of 31 Dec 2018) Total payout of dividend and extra dividend EUR 145.3 million Notes 1. DNA's guidance for 2019 is disclosed includes the impact of adoption IFRS16 as of 1 January 2019. 2. Operative capex is capital expenditure excluding spectrum license payments and IFRS16 impact. DNA's Investor presentation, February 2019 40

View entire presentation